Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Circle Pharma to work with Pfizer on two macrocyclic peptide programs

Executive Summary

Concurrent with receiving undisclosed seed funding from Pfizer Inc. and QB3’s Mission Bay Capital, Circle Pharma Inc. (developing macrocyclic peptides) signed an agreement with the Big Pharma to develop cell permeable macrocyclic peptide therapeutics.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register